Literature DB >> 32341465

Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation.

Li-Min Liang1, Jun-Jie Zhou1, Feng Xu1, Pei-Hua Liu1, Lan Qin1, Li Liu2, Xiao-Dong Liu3.   

Abstract

Peptide transporter 1 (PepT1), highly expressed on the apical membrane of enterocytes, is involved in energy balance and mediates intestinal absorption of peptidomimetic drugs. In this study, we investigated whether and how diabetes affected the function and expression of intestinal PepT1. Diabetes was induced in rats by combination of high-fat diet and low dose streptozocin injection. Pharmacokinetics study demonstrated that diabetes significantly decreased plasma exposures of cephalexin and acyclovir following oral administration of cephalexin and valacyclovir, respectively. Single-pass intestinal perfusion analysis showed that diabetes remarkably decreased cephalexin absorption, which was associated with decreased expression of intestinal PepT1 protein. We assessed the levels of bile acids in intestine of diabetic rats, and found that diabetic rats exhibited significantly higher levels of chenodeoxycholic acid (CDCA), cholic acid (CA) and glycocholic acid (GCA), and lower levels of lithocholic acid (LCA) and hyodeoxycholic acid (HDCA) than control rats; intestinal deoxycholic acid (DCA) levels were unaltered. In Caco-2 cells, the 6 bile acids remarkably decreased expression of PepT1 protein with CDCA causing the strongest inhibition, whereas TNF-α, LPS and insulin little affected expression of PepT1 protein; short-chain fatty acids induced rather than decreased expression of PepT1 protein. Farnesoid X receptor (FXR) inhibitor glycine-β-muricholic acid or FXR knockdown reversed the downregulation of PepT1 expression by CDCA and GW4064 (another FXR agonist). In diabetic rats, the expression of intestinal FXR protein was markedly increased. Oral administration of CDCA (90, 180 mg·kg-1·d-1, for 3 weeks) dose-dependently decreased the expression and function of intestinal PepT1 in rats. In conclusion, diabetes impairs the expression and function of intestinal PepT1 partly via CDCA-mediated FXR activation.

Entities:  

Keywords:  Caco-2 cells; chenodeoxycholic acid; diabetes; farnesoid X receptor; intestine; peptide transporter 1

Mesh:

Substances:

Year:  2020        PMID: 32341465      PMCID: PMC7656584          DOI: 10.1038/s41401-020-0408-4

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  60 in total

1.  In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation.

Authors:  Bei Yang; David E Smith
Journal:  Pharm Res       Date:  2017-08-02       Impact factor: 4.200

2.  High-fat diet affects gut nutrients transporters in hypo and hyperthyroid mice by PPAR-a independent mechanism.

Authors:  Mariana Cerqueira Losacco; Carolina Fernanda Theodora de Almeida; Andressa Harumi Torelli Hijo; Paula Bargi-Souza; Patricia Gama; Maria Tereza Nunes; Francemilson Goulart-Silva
Journal:  Life Sci       Date:  2018-04-04       Impact factor: 5.037

3.  Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate-Peroxisome Proliferator-Activated Receptor-γ Activation.

Authors:  Feng Xu; Liang Zhu; Chaoqun Qian; Junjie Zhou; Donghao Geng; Ping Li; Wenjing Xuan; Fangge Wu; Kaijing Zhao; Weimin Kong; Yuanyuan Qin; Limin Liang; Li Liu; Xiaodong Liu
Journal:  Drug Metab Dispos       Date:  2019-03-28       Impact factor: 3.922

4.  Gene ablation for PEPT1 in mice abolishes the effects of dipeptides on small intestinal fluid absorption, short-circuit current, and intracellular pH.

Authors:  Mingmin Chen; Anurag Singh; Fang Xiao; Ulrike Dringenberg; Jian Wang; Regina Engelhardt; Sunil Yeruva; Isabel Rubio-Aliaga; Anna-Maria Nässl; Gabor Kottra; Hannelore Daniel; Ursula Seidler
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

5.  Differential effect of type I and type II diabetes mellitus on serum ampicillin levels.

Authors:  C Adithan; G Sriram; R P Swaminathan; C H Shashindran; J S Bapna; M Krishnan; S Chandrasekar
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1989-10

6.  Disturbed intestinal nitrogen homeostasis in a mouse model of high-fat diet-induced obesity and glucose intolerance.

Authors:  Thi Thu Huong Do; Patrick Hindlet; Anne-Judith Waligora-Dupriet; Nathalie Kapel; Nathalie Neveux; Virginie Mignon; Claudine Deloménie; Robert Farinotti; Bruno Fève; Marion Buyse
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-01-14       Impact factor: 4.310

7.  Significance of peptide transporter 1 in the intestinal permeability of valacyclovir in wild-type and PepT1 knockout mice.

Authors:  Bei Yang; David E Smith
Journal:  Drug Metab Dispos       Date:  2012-12-21       Impact factor: 3.922

8.  Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited.

Authors:  Ilka Knütter; Claudia Wollesky; Gabor Kottra; Martin G Hahn; Wiebke Fischer; Katja Zebisch; Reinhard H H Neubert; Hannelore Daniel; Matthias Brandsch
Journal:  J Pharmacol Exp Ther       Date:  2008-08-19       Impact factor: 4.030

9.  Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.

Authors:  Agnès Poirier; Sara Belli; Christoph Funk; Michael B Otteneder; Renée Portmann; Katja Heinig; Eric Prinssen; Stanley E Lazic; Craig R Rayner; Gerhard Hoffmann; Thomas Singer; David E Smith; Franz Schuler
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

10.  Regulation of oligopeptide transporter (Pept-1) in experimental diabetes.

Authors:  Archana Gangopadhyay; Manikkavasagar Thamotharan; Siamak A Adibi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-07       Impact factor: 4.052

View more
  6 in total

1.  Transcriptional Regulation of Solute Carrier (SLC) Drug Transporters.

Authors:  Shiwei Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2022-05-29       Impact factor: 3.579

2.  Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.

Authors:  Zeyu Zhang; Maolin Luo; Yongping Lu; Weifeng Feng; Hongwei Wu; Lijing Fan; Baozhang Guan; Yong Dai; Donge Tang; Xiangnan Dong; Chen Yun; Berthold Hocher; Haiping Liu; Qiang Li; Lianghong Yin
Journal:  Int Urol Nephrol       Date:  2022-10-18       Impact factor: 2.266

3.  Shaoyao-Gancao Decoction Ameliorates the Inflammation State in Polycystic Ovary Syndrome Rats via Remodeling Gut Microbiota and Suppressing the TLR4/NF-κB Pathway.

Authors:  Zhuang-Peng Chang; Gui-Feng Deng; Yun-Yun Shao; Ding Xu; Yi-Nan Zhao; Yi-Fan Sun; Shi-Quan Zhang; Rui-Gang Hou; Jun-Jin Liu
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

4.  Amentoflavone-Enriched Selaginella rossii Warb. Suppresses Body Weight and Hyperglycemia by Inhibiting Intestinal Lipid Absorption in Mice Fed a High-Fat Diet.

Authors:  Hwa Lee; Seona Cho; Soo-Yong Kim; Jeongha Ju; Sang Woo Lee; Sangho Choi; Hulin Li; Renzhe Piao; Ho-Yong Park; Tae-Sook Jeong
Journal:  Life (Basel)       Date:  2022-03-24

Review 5.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

Review 6.  Effect of different bile acids on the intestine through enterohepatic circulation based on FXR.

Authors:  Junwei Xiang; Zhengyan Zhang; Hongyi Xie; Chengcheng Zhang; Yan Bai; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.